Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLESSA vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
400 mg orally once daily with food.
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol is metabolized primarily via CYP3A4; desogestrel is converted to active metabolite etonogestrel via CYP2C9 and CYP2C19.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Desogestrel: 99.7% (SHBG); ethinyl estradiol: 98.5% (albumin, SHBG).
98% bound to albumin
Desogestrel: 1.0-1.5 L/kg (extensive tissue distribution); ethinyl estradiol: 0.15-0.35 L/kg (limited).
0.2-0.3 L/kg; indicates limited extravascular distribution
Desogestrel: 76% (oral); ethinyl estradiol: 55% (oral, variable due to first-pass metabolism).
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (Cr Cl <30 m L/min); use with caution.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in Child-Pugh class C (severe hepatic impairment). For mild to moderate (Child-Pugh A or B), use with caution: reduce estrogen dose or discontinue if intolerance occurs.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use before menarche. For postmenarchal adolescents, dose same as adults: 0.15 mg desogestrel/0.02 mg ethinyl estradiol daily.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for postmenopausal women. No studies in geriatric population; use not recommended due to lack of benefit and increased thromboembolic risk with age.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptives. Risk increases with age and amount smoked (especially in women >35 years who smoke). Women should not use CYCLESSA if they smoke cigarettes and are over 35 years old.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism),Cerebrovascular disease,Cardiovascular disease including myocardial infarction,Liver disease including hepatic adenoma,Increased blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache,Bleeding irregularities
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Known or suspected pregnancy,Current or past breast cancer or other estrogen-sensitive cancer,Current or past deep vein thrombosis or pulmonary embolism,Current or history of thrombogenic valvular or rhythm disease,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Severe liver disease or liver tumor,Undiagnosed abnormal uterine bleeding,Age >35 years and smoking
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Alcohol does not affect efficacy but may increase risk of liver damage with high doses.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
First trimester: The use of combined hormonal contraceptives containing desogestrel and ethinyl estradiol is not associated with an increased risk of major birth defects. Discontinuation due to first-trimester exposure is not indicated. Second and third trimesters: Prolonged exposure to estrogen-progestin combinations has been associated with rare risks such as congenital heart defects and limb reduction defects in case-control studies, but absolute risk is low. Fetal risk from inadvertent use in pregnancy is minimal; termination not recommended.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. Studies with combined oral contraceptives suggest possible effects on milk production and composition; use during lactation should be postponed until the infant is weaned or at least 6 months postpartum. M/P ratio for ethinyl estradiol and desogestrel metabolites is not well established; limited data suggest low transfer.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
No dose adjustments are applicable as CYCLESSA is contraindicated during pregnancy. In the event of inadvertent use, the drug should be discontinued as soon as pregnancy is confirmed. No pharmacokinetic-based dose changes are required because use is not recommended in pregnancy.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
CYCLESSA (desogestrel/ethinyl estradiol) is a monophasic oral contraceptive. It may be used off-label for acne treatment. Breakthrough bleeding is common in the first 3 cycles. CYP3A4 inducers (e.g., rifampin) reduce efficacy; consider backup contraception.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one tablet daily at the same time, even if no intercourse.,Start on the first day of menstrual period or first Sunday after period starts.,Use backup contraception for first 7 days if starting after day 5.,Missed pill: take as soon as remembered. If more than 2 missed, use backup method.,Vomiting or diarrhea may reduce effectiveness.,Report unexplained leg pain, chest pain, severe headache, or vision changes.,Smoking increases risk of serious cardiovascular side effects, especially if over 35.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLESSA vs ADQUEY, answered by our medical review team.
CYCLESSA is a Oral Contraceptive that works by Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLESSA and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLESSA is: One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLESSA and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLESSA is classified as Category C. First trimester: The use of combined hormonal contraceptives containing desogestrel and ethinyl estradiol is not associated with an increased risk of major birth defects. Discontin. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.